Pharmacological treatments in ARDS; a state-of-the-art update


Published in:
BMC Medicine

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2013 Boyle et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Download date:29. Dec. 2018
Pharmacological treatments in ARDS; a state-of-the-art update

Andrew James Boyle, Rob Mac Sweeney and Daniel Francis McAuley

Abstract

Despite its high incidence and devastating outcomes, acute respiratory distress syndrome (ARDS) has no specific treatment, with effective therapy currently limited to minimizing potentially harmful ventilation and avoiding a positive fluid balance. Many pharmacological therapies have been investigated with limited success to date. In this review article we provide a state-of-the-art update on recent and ongoing trials, as well as reviewing promising future pharmacological therapies in ARDS.

Keywords: Acute lung injury, Acute respiratory distress syndrome

Introduction

Despite its high incidence and devastating outcomes [1,2], acute respiratory distress syndrome (ARDS) has no specific treatment, with effective therapy currently limited to minimizing potentially harmful ventilation and avoiding a positive fluid balance. ARDS is characterized by breakdown of the alveolar-capillary barrier, leading to flooding of the alveolar space producing the classical chest radiograph of bilateral pulmonary infiltrates. This non-cardiogenic pulmonary edema is associated with impaired oxygenation, as measured by the PaO₂/FiO₂ (P/F) ratio, with a lower P/F ratio indicating more severe hypoxia. Acute lung injury (ALI) is defined as a P/F ratio <300 mmHg (40kPa) and ARDS is a sub-group defined on the basis of more severely impaired oxygenation with a P/F ratio <200 mmHg (26.7 kPa).

Since it was first described in 1967 [3], and despite over 40 years of research, few pharmacological therapies have emerged for ARDS. We limited the search strategy for this state-of-the-art update review to recent randomized controlled trials and meta-analyses, as well as a review of promising potential future pharmacological therapies in ARDS in an adult setting.

Neuromuscular blockade

Lung protective ventilation can be achieved in the majority of patients without using neuromuscular blockade (NMB) [4]; however, initial small studies eliminating patient effort via skeletal muscle inhibition with NMB improved patient-ventilator synchrony, as evidenced by reduced airway pressures and improved chest wall compliance. Therefore, in the severely hypoxemic ARDS patient, NMB may permit lower-pressure, lower-tidal volume ventilation with a consequent reduction in ventilator-induced lung injury. These beneficial effects led to a multi-center, randomized, placebo-controlled trial to assess the effect of NMB upon mortality [5] (Table 1). This showed that infusion with cisatracuriumbesylate within 48 hours of mechanical ventilation in patients with moderate ARDS improved 90-day survival. However, no difference was noted between the intervention and placebo groups until Day 20. The biological mechanism by which NMB improves late but not early outcome is unclear. While promising, the protective effect of neuromuscular blockade needs to be confirmed in a further phase 3 trial.

β-adrenergic agonists

Alveolar edema is a central feature of ARDS, contributing to limitation of gaseous exchange and ventilatory failure. Experimental data suggest β-adrenergic agonists could accelerate alveolar fluid clearance, as well as provide cytoprotection, increased surfactant secretion and decreased endothelial permeability.
Table 1 Characteristics of trials to date

<table>
<thead>
<tr>
<th>Study title and abbreviation</th>
<th>Design (all placebo-controlled)</th>
<th>Population of ALI/ARDS</th>
<th>Number recruited</th>
<th>Intervention</th>
<th>Primary outcome</th>
<th>Result (intervention vs control)</th>
<th>Mortality (intervention vs control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuromuscular Blockade in Early ARDS [5]</td>
<td>Phase 2 RCT A) 48 hours B) &lt;150</td>
<td>340</td>
<td>Cisatracuriumbesylate: 15 mg initially, then 37.5 mg per hour for 48 hours</td>
<td>90-day survival</td>
<td>31.6% vs 40.7% (P=0.08)</td>
<td>28-day: 23.7% vs 33.3% (P=0.05)</td>
<td></td>
</tr>
<tr>
<td>The β-Agonist Lung Injury Trial (BALTI) [6]</td>
<td>Phase 1 RCT A) 48 hours B) &lt;300</td>
<td>40</td>
<td>Intravenous (IV) salbutamol for seven days (15 μg kg⁻¹ h⁻¹)</td>
<td>Extravascular lung water (DLVO) at Day 7</td>
<td>9.2 ± 6 vs 13.2 ± 3 ml kg⁻¹ (P=0.04)</td>
<td>28-day: 58% vs 66% (P=0.04)</td>
<td></td>
</tr>
<tr>
<td>Randomized, Placebo-Controlled Clinical Trial of an Aerosolized β2-Agonist for Treatment of Acute Lung Injury (ALTA) [7]</td>
<td>Phase 2 RCT A) 48 hours B) &lt;300</td>
<td>282</td>
<td>Inhaled salbutamol for ten days/24 hours after extubation</td>
<td>Ventilator-free days (VFD)</td>
<td>Stopped early</td>
<td>Death before discharge: 24.3 ± 3.5 vs 18.5 ± 3.4 (P=0.261)</td>
<td></td>
</tr>
<tr>
<td>Effect of Intravenous β-2 Agonist Treatment on Clinical Outcomes in Acute Respiratory Distress Syndrome (BALTI-2) [8]</td>
<td>Phase 2 RCT A) 72 hours B) &lt;200</td>
<td>326</td>
<td>IV salbutamol for seven days (15 μg kg⁻¹ (ideal body weight) h⁻¹)</td>
<td>28-day mortality</td>
<td>Stopped early</td>
<td>34% vs 23% (P=0.03)</td>
<td></td>
</tr>
<tr>
<td>Neutrophil Elastase Inhibition in Acute Lung Injury (STRIVE) [9]</td>
<td>Phase 3 RCT A) 48 hours B) &lt;300</td>
<td>492</td>
<td>Sivelestat infusion</td>
<td>1. 28-day mortality2. VFD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy and Safety of Corticosteroids for Persistent ARDS (LaSRS) [14]</td>
<td>Phase 2 RCT A) 7 to 28 days B) P/F &lt;200</td>
<td>180</td>
<td>Moderate-dose IV methylprednisolone, for up to 25 days</td>
<td>60-day mortality</td>
<td>29.2% vs 28.6% (P=1.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone Infusion in Early Severe ARDS [15]</td>
<td>Phase 1 RCT A) 72 hours B) &lt;300</td>
<td>91</td>
<td>Low-dose IV methylprednisolone, for up to 28 days</td>
<td>Improvement in Lung Injury Score by Day 7</td>
<td>69.8% vs 35.7% (P=0.002)</td>
<td>Hospital survival 76.2% vs 57.1% (P=0.07)</td>
<td></td>
</tr>
<tr>
<td>A Randomized Clinical Trial of Hydroxymethylglutaryl-Coenzyme A Reductase Inhibition for Acute Lung Injury (HARP) [19]</td>
<td>Phase 2 RCT A) 48 hours B) &lt;300</td>
<td>60</td>
<td>Simvastatin 80 mg daily, up to 14 days</td>
<td>Reduction in EVLW indexed to actual body weight</td>
<td>13.7 vs 13.4 (P=0.90)</td>
<td>Hospital survival: 19 vs 19 (P=1.0)</td>
<td></td>
</tr>
<tr>
<td>Nebulized Heparin is Associated with Fewer Days of Mechanical Ventilation in Critically Ill Patients: a Randomized Controlled Trial [21]</td>
<td>Phase 2 RCT Patients expected to require ventilation for &gt;48 hours, and within 24 hours of ventilation</td>
<td>50</td>
<td>Heparin 25,000 units every 4 to 6 hours, for up to 14 days</td>
<td>Average daily P/F ratio</td>
<td>194.2 ± 62.8 vs 187 ± 38.6 mmHg (P=0.06)</td>
<td>Improvements in secondary outcomes</td>
<td></td>
</tr>
</tbody>
</table>

Based on the proposed effect upon alveolar fluid clearance, the β-Agonist Lung Injury Trial (BALTI) randomized 60 patients to IV salbutamol or placebo for seven days [6]. In this small, single center study, salbutamol therapy significantly reduced extravascular lung water at Day 7 compared with placebo (Table 1). Subsequently, two large multi-center, randomized placebo-controlled trials were initiated. The first American study, ALTA (Albuterol Treatment for Acute Lung Injury) [7], enrolled 282 patients with ALI, but failed to demonstrate a difference in ventilator-free days between those receiving inhaled β-agonist therapy and those given placebo, and was stopped early as it breached the futility boundary (Table 1). In the most severely ill, as defined by the presence of shock at randomization, length of stay was significantly increased, suggesting worse outcome in this sub-group. BALTI-2 was a concurrent UK multi-center study investigating intravenous salbutamol in patients with ARDS, but was terminated early due to excess...
mortality in the group receiving IV salbutamol [8] (Table 1).

On the basis of these larger trials, β-agonists should be avoided in patients with ALI. It is hypothesized that β-agonists may have a harmful cardiac effect, stimulating tachyarrhythmias and cardiac ischemia, resulting in a poorer outcome.

Neutrophil elastase inhibitors
Neutrophil elastase (NE) is a serine protease found in neutrophil granules and has a range of physiological effects, including anti-microbial actions and modification of tissue repair and inflammation. Excessive NE is capable of degrading endothelial basement membrane, and has been implicated in the pathogenesis of ARDS. Following a positive study in Japan, silvelestat, a neutrophil elastase inhibitor, was investigated in an international randomized, double-blind, placebo-controlled, multi-center phase III trial (STRIVE) [9] (Table 1). The study was stopped prematurely due to an increase in 180-day all-cause mortality.

A more recent meta-analysis of eight clinical trials (including STRIVE) investigating silvelestat has shown it to have no effect on short-term mortality, and a worse outcome for 180-day mortality (Risk Ratio (RR) 1.27, CI 1.00 to 1.62) [10].

Corticosteroids
Given their effective anti-inflammatory properties, there has been extensive interest in the potential role of corticosteroids in both the prevention and treatment of ARDS. Different regimens have been investigated, varying from short courses of high-dose steroids to prolonged courses of lower doses.

High dose corticosteroids do not prevent ARDS in at risk subjects [11-13]. Therapeutically, both high-dose and moderate-dose steroids have so far failed to demonstrate efficacy in ARDS. An ARDSnet randomized, double-blind trial in 180 patients with ARDS for more than seven days, showed no effect of prolonged treatment with moderate-dose methylprednisolone compared to placebo [14] (Table 1). Although patients were liberated from mechanical ventilation earlier, patients receiving methylprednisolone were more likely to resume assisted ventilation, which was thought to be secondary to neuromuscular effects. In addition, initiation of treatment after 14 days of ARDS was associated with a harmful effect, with increased mortality at 60 and 180 days.

However, the role of low-dose corticosteroids in established ARDS remains uncertain, with one study of 91 patients demonstrating prolonged low-dose methylprednisolone therapy reduces severity of lung injury by Day 7 of treatment [15] (Table 1).

Despite a systematic review [16] and meta-analysis [17], the role of steroids in ARDS remains unclear, and in light of ongoing uncertainty, further trials are both planned (NCT01731795) and on-going (NCT01284452) (Table 2). It is also worth highlighting that the studies included used what are now considered injurious ventilation strategies. It remains uncertain if steroids provide benefit when combined with lung protective (and, therefore, less inflammatory) ventilator strategies.

Statins
HMG CoA-reductase inhibitors (statins) have a range of physiological effects beyond their role in cholesterol reduction, including anti-inflammatory actions and endothelial function modulation. Their effect on pulmonary inflammation was confirmed during a randomized, double-blind, placebo-controlled pre-clinical study, where simvastatin demonstrated a variety of anti-inflammatory effects during an inhaled lipopolysaccharide (LPS) model of ARDS in healthy volunteers [18].

A small phase II clinical trial in patients with ARDS (HARP) [19], suggested a potential role for simvastatin in the treatment of ARDS, with benefit in pulmonary and non-pulmonary organ dysfunction with no excess of adverse events in the intervention group (Table 1). Two larger trials are presently recruiting in the UK and Ireland (HARP-2 [20]) and in the USA (SAILS, NCT00979121), investigating simvastatin and rosuvastatin, respectively. A phase two trial in Oklahoma was recently terminated due to poor enrollment (NCT01195428).

Heparin
During the inflammatory process of ARDS fibrin is deposited throughout the alveolus, both intra- and extravascularly, impairing oxygenation. Experimental data show that, among other effects, heparin can reduce fibrin deposition. This led to a small study investigating the efficacy of nebulized heparin in patients at risk for ARDS [21]. Although there was no significant effect on the P/F ratio, this study suggested heparin may increase the number of ventilator-free days (VFD) (Table 1). The results of this trial have prompted further studies investigating the long-term impact of nebulized heparin in patients at risk of ARDS (ACTRN12612000418875) (Table 2).

Aspirin
During ARDS, platelets become activated and play an important role in disease progression by sequestering within the lung, forming micro-thrombi and attracting inflammatory cells to injured tissue. The potent anti-platelet effect of aspirin may offer a therapeutic approach to this pathological process. Observational data associated pre-hospital anti-platelet use with a reduction in subsequent ARDS incidence [22]. This finding was repeated in a separate study, although when propensity to receive aspirin was included in the analysis, the effect was lost [23].
Clinical trials are planned to investigate the effect of aspirin on reducing inflammation in a human model of ARDS (ARENA, NCT01659307), while others are ongoing to assess the impact of aspirin in the prevention of ARDS (LIPS-A, NCT01504867) (Table 2).

### Table 2 Ongoing/planned clinical trials in ARDS

<table>
<thead>
<tr>
<th>Study reference</th>
<th>Study title and abbreviation</th>
<th>Design</th>
<th>Population A) Timing B) P/F ratio</th>
<th>Anticipated enrollment</th>
<th>Intervention</th>
<th>Primary outcome</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01731795</td>
<td>Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome (DEXA-ARDS)</td>
<td>Phase 2/3 RCT</td>
<td>A) 24 hours from ARDS onset B) &lt;200</td>
<td>314</td>
<td>Dexamethasone (20 mg/day for five days, then 10 mg/day for five days)</td>
<td>Ventilator-free days</td>
<td>Not yet recruiting</td>
</tr>
<tr>
<td>NCT01284452</td>
<td>Efficacy of hydrocortisone in treatment of severe sepsis/septic shock patients with ALI/ARDS</td>
<td>Phase 2/3 RCT</td>
<td>A) 12 hours from organ dysfunction B) &lt;300</td>
<td>194</td>
<td>Hydrocortisone 50 mg every six hours for seven days</td>
<td>28-day all-cause mortality</td>
<td>Recruiting</td>
</tr>
<tr>
<td>ISRCTN88244364</td>
<td>Simvastatin in acute lung injury (HARP-2)</td>
<td>Phase 2/3 RCT</td>
<td>A) 48 hours from ALI onset B) &lt;300</td>
<td>540</td>
<td>Simvastatin 80 mg daily</td>
<td>Ventilator-free days</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT00979121</td>
<td>Statins for Acutely Injured Lungs from Sepsis (SAILS)</td>
<td>Phase 3 RCT</td>
<td>A) 48 hours from ALI onset B) &lt;300</td>
<td>1000</td>
<td>Rosuvastatin 20 mg daily</td>
<td>Hospital mortality Day 60</td>
<td>Recruiting</td>
</tr>
<tr>
<td>ACTRN12612000418875</td>
<td>Nebulized heparin for lung injury</td>
<td>Phase 2 RCT</td>
<td>A) Within 24 hours of mechanical ventilation in at-risk patients B) &lt;300</td>
<td>256</td>
<td>Nebulised Heparin 25,000 international units, every six hours for up to 10 days</td>
<td>Physical function assessed using physical function component of SF-36 health survey</td>
<td>Not yet recruiting</td>
</tr>
<tr>
<td>NCT01659307</td>
<td>The effect of Aspirin on REDucing Nflammation in human in vivo model of Acute lung injury (ARENA)</td>
<td>Phase 2 RCT</td>
<td>Healthy, non-smoking adults, using an LPS model of ALI</td>
<td>33</td>
<td>Aspirin 75 mg or Aspirin 1,200 mg</td>
<td>Bronchialveolar lavage intraleukin-8 concentration</td>
<td>Not yet recruiting</td>
</tr>
<tr>
<td>NCT01504867</td>
<td>LIPS-A: Lung Injury Prevention Study with Aspirin</td>
<td>Phase 2 RCT</td>
<td>Adults admitted to hospital via the emergency department at high-risk of developing ALI</td>
<td>400</td>
<td>Aspirin 325 mg Day 1, then 81 mg daily days 2 to 7</td>
<td>Development of ARDS</td>
<td>Recruiting</td>
</tr>
<tr>
<td>ISRCTN95690673</td>
<td>Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction (KARE)</td>
<td>Phase 2 RCT</td>
<td>A) 48 hours from ALI onset B) &lt;300</td>
<td>60</td>
<td>Palifermin 60 μg/kg IV daily for up to six days</td>
<td>Oxygenation index at Day 7</td>
<td>Recruiting</td>
</tr>
<tr>
<td>ISRCTN27673620</td>
<td>Vitamin D Replacement to Prevent Acute Lung Injury following Oesophagectomy (VINDALOO)</td>
<td>Phase 1/2 RCT</td>
<td>Adults undergoing planned transthoracic esophagectomy</td>
<td>80</td>
<td>Oral Vitamin D (100,000 IU)</td>
<td>EVLV at end of procedure</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT00789685</td>
<td>Safety, tolerability and preliminary efficacy of FP-1201 in ALI and ARDS</td>
<td>Phase 1/2 Non-randomized</td>
<td>A) 48 hours from ALI onset B) &lt;300</td>
<td>37</td>
<td>Interferon-β, increasing dose over six days</td>
<td>Clinically significant treatment emergent events, and all-cause mortality</td>
<td>Completed</td>
</tr>
</tbody>
</table>

Angiotensin converting enzyme inhibitors/angiotensin receptor blockers

The renin-angiotensin system (RAS) plays an important role in the pathogenesis of ARDS, with angiotensin converting enzyme 1 (ACE1) directing a RAS signal to...
the angiotensin 1 receptor (AT1R), mediating alveolar vasoconstriction, permeability and fibrosis. A variant of ACE1, ACE2, diverts a RAS signal to AT2R, which promotes alveolar vasodilation, decreased permeability and apoptosis, thus opposing the alternative potentially injurious signaling mechanism [24]. Angiotensin receptor blockers attenuate ventilator-induced lung injury in animal models [25], and ACE-inhibitor or angiotensin receptor blocker therapy on discharge were associated with reduced mortality in acute respiratory failure patients [26]. Collectively, these data provide encouragement for future clinical trials in this area.

**Stem cell therapy**

Regenerative medicine is an emerging field, using stem cells or growth factors to aid the repair of damaged tissue and organs. Stem cells exhibit anti-inflammatory, immunomodulatory and reparative effects, largely mediated through secreted growth factors, although cell to cell contact between stem cells and alveoli also mediates important effects [27].

This prompts questions regarding the optimal delivery of stem cell therapy, as animal models of ARDS have shown survival to increase when treatment was delivered directly to the bronchial tree [28]. In addition, recent evidence in *ex-vivo* human lung models of ALI support the investigation of delivering stem cells directly to the lung [29]. Clinical trials are awaited in this promising area.

**Growth factors**

Keratinocyte growth factor (KGF), an epithelial growth factor secreted by fibroblasts, has an important role in lung injury repair [30]. It increases alveolar cellular proliferation in ARDS, particularly of type II alveolar cells, enhancing repair. KGF may also have a role during the injurious process, reducing endothelial permeability and alveolar edema [30], and improving alveolar fluid clearance [31]. Following the completion of a small preclinical trial testing KGF in an LPS-model of ARDS (ISRCTN98813895), for which results are awaited, a phase II trial has commenced investigating the efficacy and safety of intravenous KGF (palifermin) in ARDS [32] (ISRCTN95690673) (Table 2).

**Other potential therapies**

Following data showing an immunomodulatory effect of vitamin D, animal models of ALI demonstrate that intratracheal administration of vitamin D can reduce neutrophil recruitment to the lung [33], which has obvious implications for future therapy in ALI. Vitamin D is currently being tested in patients at risk of developing ALI following esophagectomy [34] (Table 2).

Used in the management of multiple sclerosis, interferon-β (IFN-β) has been shown *in vitro* and in animal models of ALI to reduce vascular leakage and improve capillary endothelial barrier function [35]. IFN-β therapy has been studied in a phase I/II study in the UK, for which results are awaited (NCT00789685) (Table 2).

Finally, vascular endothelial growth factor (VEGF), an important molecule in the control of vascular permeability, has been found to be elevated in patients with ARDS [36]. The presence of VEGF inhibitors may prompt future randomized-controlled trials.

Other therapies, including the use of nitric oxide [37], prostacyclin [38] and surfactant [39], have been investigated and found to be ineffective. These additional therapies, plus others, are beyond the scope of this review, but have been covered in recent review articles [40,41].

**Conclusion**

Despite many interventions being studied, to date there has been little success in developing effective pharmacological therapies for the management of ARDS. However, given the high associated morbidity and mortality, pressure remains to continue efforts to improve outcomes. Increasing numbers of pharmacological therapies are being investigated, and with encouraging pre-clinical and early clinical results, it is expected that over the coming years some will develop into useful agents for the prevention and treatment of ARDS.

**Abbreviations**

ACE: Angiotensin converting enzyme; ALI: Acute lung injury; AT1R: Angiotensin 1 receptor; AT2R: Angiotensin 2 receptor; BALTI: β-agonist Lung Injury Trial; CI: Confidence interval; DEXA-ARDS: Efficacy study of dexamethasone to treat the acute respiratory distress syndrome; EVLW: Extravascular lung water; HARP: A randomized clinical trial of hydroxymethylglutaryl-β-coenzyme a reductase inhibition for acute lung injury; IFN-β: Interferon-β; IV: Intravenous; KGF: Keratinocyte growth factor; LIPS-A: Lung injury prevention study with aspirin; LPS: Lipopolysaccharide; NE: Neutrophil elastase; NMB: Neuromuscular blockade; P/F ratio: PaO2/FiO2 ratio; RAS: Renin-angiotensin system; RR: Relative risk; SAILS: Statins for acutely injured lungs from sepsis; STRIVE: Neutrophil elastase inhibition in acute lung injury; VEGF: Vascular endothelial growth factor; VFD: Ventilator free days.

**Competing interests**

DFM has performed paid consultancy work for GlaxoSmithKline relating to acute lung injury, is a member of the advisory boards for treatments of acute lung injury, and has been paid for undertaking bronchoscopy as part of a clinical trial. DFM has also received fees for lecturing for AstraZenica; and has a patent submitted for a novel treatment for ARDS. AJB and RMS have no competing interests to declare.

**Authors’ contributions**

All authors contributed to the design of the paper. AJB wrote the initial manuscript, RMS and DFM edited it. All authors read and approved the final manuscript.
Reference


Cite this article as: Boyle et al.: Pharmacological treatments in ARDS; a state-of-the-art update. *BMC Medicine* 2013 11:166.